全文获取类型
收费全文 | 6519篇 |
免费 | 363篇 |
国内免费 | 44篇 |
专业分类
耳鼻咽喉 | 9篇 |
儿科学 | 104篇 |
妇产科学 | 138篇 |
基础医学 | 1314篇 |
口腔科学 | 69篇 |
临床医学 | 865篇 |
内科学 | 1317篇 |
皮肤病学 | 97篇 |
神经病学 | 431篇 |
特种医学 | 198篇 |
外科学 | 608篇 |
综合类 | 191篇 |
预防医学 | 311篇 |
眼科学 | 55篇 |
药学 | 630篇 |
中国医学 | 10篇 |
肿瘤学 | 579篇 |
出版年
2023年 | 260篇 |
2022年 | 268篇 |
2021年 | 365篇 |
2020年 | 367篇 |
2019年 | 234篇 |
2018年 | 236篇 |
2017年 | 229篇 |
2016年 | 275篇 |
2015年 | 314篇 |
2014年 | 538篇 |
2013年 | 384篇 |
2012年 | 250篇 |
2011年 | 213篇 |
2010年 | 371篇 |
2009年 | 385篇 |
2008年 | 166篇 |
2007年 | 173篇 |
2006年 | 147篇 |
2005年 | 134篇 |
2004年 | 88篇 |
2003年 | 89篇 |
2002年 | 96篇 |
2001年 | 83篇 |
2000年 | 61篇 |
1999年 | 89篇 |
1998年 | 78篇 |
1997年 | 87篇 |
1996年 | 85篇 |
1995年 | 84篇 |
1994年 | 52篇 |
1993年 | 52篇 |
1992年 | 60篇 |
1991年 | 50篇 |
1990年 | 40篇 |
1989年 | 33篇 |
1988年 | 48篇 |
1987年 | 24篇 |
1986年 | 25篇 |
1985年 | 37篇 |
1984年 | 39篇 |
1983年 | 34篇 |
1982年 | 28篇 |
1981年 | 33篇 |
1980年 | 22篇 |
1979年 | 35篇 |
1978年 | 16篇 |
1977年 | 19篇 |
1976年 | 19篇 |
1975年 | 17篇 |
1974年 | 21篇 |
排序方式: 共有6926条查询结果,搜索用时 15 毫秒
11.
12.
13.
《Journal of thoracic oncology》2019,14(10):1818-1827
IntroductionProgrammed death ligand 1 (PD-L1) expression is a predictive biomarker for patient response to nivolumab in nonsquamous NSCLC. However, the number of biopsy samples and tumor cells (TCs) required to assess PD-L1 expression remains unclear.MethodsA total of 222 biopsy samples from 80 patients with nonsquamous NSCLC treated with nivolumab were collected. Number of TCs and PD-L1 score were compared among the sample containing the largest number of TCs (Max-TC), the sample containing the smallest number of TCs (Min-TC), and the total samples from each patient. The impact of the number of samples and TCs on the prediction of patient response to nivolumab with use of PD-L1 scores was evaluated.ResultsThere was a mismatch in PD-L1 scores less than 1% and those of at least 1% between Max-TC and the total samples in one patient (1%) and between Max-TC and Min-TC in six patients (8%). The optimal number of TCs to match PD-L1 expression less than 1% versus at least 1% between Max-TC and Min-TC was 100 (sensitivity = 0.676 and 1 – specificity = 0.333). PD-L1 expression of at least 1% in Min-TCs containing at least 100 TCs was associated with longer progression-free survival (median 7.6 versus 1.8 months [p < 0.01]) and overall survival (median not reached versus 9.9 months [p = 0.04]) compared with PD-L1 expression less than 1%. However, there were no differences in progression-free survival (median 3.9 versus 2.3 months [p = 0.37]) or overall survival (median 9.7 versus 7.6 months [p = 0.60]) between PD-L1 expression of at least 1% and PD-L1expression less than 1% in Min-TCs containing fewer than 100 TCs.ConclusionSingle biopsy samples containing at least 100 TCs are required to evaluate PD-L1 expression for predicting patient response to nivolumab. 相似文献
14.
15.
16.
17.
《Diagnostic microbiology and infectious disease》2020,96(1):114835
The in vitro activities of ceftazidime-avibactam and comparator agents were analyzed against 14,330 isolates of Pseudomonas aeruginosa from 188 centers distributed globally (except North America) from 2012 (2014 for colistin) to 2016 as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program. Susceptibility testing used in-house prepared broth microdilution panels following CLSI guidelines. Multiplex PCR assays identified the presence of β-lactamases. Ceftazidime-avibactam (MIC90 8 mg/L; 91.5% susceptibility) and colistin (N = 11,032; MIC90 2 mg/L, 96.2%) were the 2 most active agents. Susceptibility of multidrug-resistant isolates (N = 3770, 26.3%) was ≤54.4% to all agents except colistin (N = 2956; 95.2% susceptible) and ceftazidime-avibactam (68.2%). Metallo-β-lactamase–positive isolates (N = 621, 4.3%) were not susceptible to any agents except colistin (N = 504; 98.2% susceptible). Novel therapeutic options are needed for infections caused by P. aeruginosa–resistant phenotypes. 相似文献
18.
《Journal of infection and chemotherapy》2020,26(1):23-27
IntroductionAlthough peak C-reactive protein (CRP) levels are correlated with the prognosis of some diseases, there have been no reports regarding the association between peak CRP levels and mortality in patients with bacteremia. The present study aimed to determine the association between peak CRP levels and prognosis in patients with bacteremia.MethodsThis retrospective cohort study was conducted in a single tertiary hospital and included patients with bacteremia admitted to the emergency department from November 2012 to March 2017. Cox regression analysis was performed to examine the association between peak CRP levels and 30-day mortality. We also performed propensity score adjustment using potential confounding factors.ResultsOne hundred fifty-nine patients were included in the study. Peak CRP levels were significantly higher in the β-hemolytic streptococci (P = 0.001) and Streptococcus pneumoniae (P = 0.003) groups. The C-statistic of the multivariate logistic regression model for the propensity score was 0.88. For 30-day mortality, peak CRP levels >20 mg/dL did not show significance in the Cox regression analysis (hazard ratio, 0.866; 95% confidence interval, 0.489–1.537; P = 0.62). Even after propensity score adjustment, no significance was noted (hazard ratio, 0.865; 95% confidence interval, 0.399–1.876; P = 0.71).ConclusionsPeak CRP levels were not an independent predictor of mortality in patients with bacteremia in the emergency department. Clinicians should consider that patients with extremely high peak CRP levels do not necessarily have high mortality and vice versa. 相似文献
19.
20.